Švýcarsko - francouzština - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - brivaracetamum - comprimés pelliculés - brivaracetamum 25 mg, carmellosum natricum conexum corresp. natrium 0.75 mg, lactosum monohydricum 48.5 mg, betadexum, lactosum 48.25 mg, magnesii stearas, pellicule: poly(alcohol vinylicus), talcum, macrogolum 3350, e 171, e 172 (flavum), e 172 (nigrum) pro compresso obducto. - antiépileptique - synthetika

Švýcarsko - francouzština - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - brivaracetamum - comprimés pelliculés - brivaracetamum 50 mg, carmellosum natricum conexum corresp. natrium 1.5 mg, lactosum monohydricum 97 mg, betadexum, lactosum 96.5 mg, magnesii stearas, pellicule: poly(alcohol vinylicus), talcum, macrogolum 3350, e 171, e 172 (flavum), e 172 (rubrum) pro compresso obducto. - antiépileptique - synthetika

Švýcarsko - francouzština - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - brivaracetamum - comprimés pelliculés - brivaracetamum 75 mg, carmellosum natricum conexum corresp. natrium 2.25 mg, lactosum monohydricum 145.5 mg, betadexum, lactosum 144.75 mg, magnesii stearas, pellicule: poly(alcohol vinylicus), talcum, macrogolum 3350, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum) pro compresso obducto. - antiépileptique - synthetika

Švýcarsko - francouzština - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - brivaracetamum - comprimés pelliculés - brivaracetamum 100 mg, carmellosum natricum conexum corresp. natrium 3 mg, lactosum monohydricum 194 mg, betadexum, lactosum 193 mg, magnesii stearas, pellicule: poly(alcohol vinylicus), talcum, macrogolum 3350, e 171, e 172 (flavum), e 172 (nigrum) pro compresso obducto. - antiépileptique - synthetika

Švýcarsko - francouzština - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - brivaracetamum - solution buvable - brivaracetamum 50 mg, acidum citricum, natrii citras dihydricus, carmellosum natricum, sucralosum, sorbitolum 839.5 mg, glycerolum, aromatica, aqua purificata, e 218 5 mg ad solutionem pro 5 ml corresp. natrium 5.8 mg. - antiépiléptique - synthetika

Evropská unie - maltština - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - epilessija - anti-epilettiċi, - briviact huwa indikat bħala terapija aġġuntiva fit-trattament ta 'aċċessjonijiet ta' bidu parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja f'pazjenti adulti u adolexxenti minn 16-il sena b'epilessija.

Evropská unie - chorvatština - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - epilepsija - antiepileptici sredstva, - briviact je indiciran kao pomoćna terapija u liječenju parcijalnih napadaja s ili bez sekundarne generalizacije u odraslih i adolescentnih bolesnika od 16 godina s epilepsijom.

Evropská unie - italština - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - epilessia - antiepilettici, - briviact è indicato come terapia aggiuntiva nel trattamento delle crisi ad esordio parziale con o senza generalizzazione secondaria in pazienti adulti e adolescenti dai 16 anni di età con epilessia.

Tchaj-wan - čínština - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

台灣優時比貿易有限公司 台北市松山區敦化北路88號12樓之2 (54672790) - brivaracetam - 膜衣錠 - 主成分 (每錠含：) ; brivaracetam (2812002600) mg - brivaracetam - briviact適用於4歲以上局部癲癇發作病人的治療。

Tchaj-wan - čínština - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

台灣優時比貿易有限公司 台北市松山區敦化北路88號12樓之2 (54672790) - brivaracetam - 膜衣錠 - 主成分 (每錠含：) ; brivaracetam (2812002600) mg - brivaracetam - briviact適用於4歲以上局部癲癇發作病人的治療。